Vcanbio Cell & Gene Engineering Corp (600645.SS) Stock Price
Vcanbio Cell & Gene Engineering Corp Price
Revenue has compounded at 6.9% per year over the past 19 years to 1.45 B CNY. Earnings per share have grown at 13.1% per year over the last 19 years. Vcanbio Cell & Gene Engineering Corp's net margin stands at 7.8%, down from 10.1% several years earlier. The stock trades about 13% above its 52-week low.
Vcanbio Cell & Gene Engineering Corp stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Vcanbio Cell & Gene Engineering Corp over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Vcanbio Cell & Gene Engineering Corp stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Vcanbio Cell & Gene Engineering Corp's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Vcanbio Cell & Gene Engineering Corp Price |
|---|---|
| 9/21/2026 | 18.86 CNY |
| 9/18/2026 | 18.19 CNY |
| 9/17/2026 | 18.05 CNY |
| 9/16/2026 | 17.87 CNY |
| 9/15/2026 | 17.83 CNY |
| 9/14/2026 | 17.92 CNY |
| 9/11/2026 | 17.78 CNY |
| 9/10/2026 | 18.04 CNY |
| 9/9/2026 | 18.39 CNY |
| 9/8/2026 | 18.74 CNY |
| 9/7/2026 | 18.64 CNY |
| 9/4/2026 | 18.62 CNY |
| 9/3/2026 | 18.71 CNY |
| 9/2/2026 | 18.98 CNY |
| 9/1/2026 | 19.26 CNY |
| 8/31/2026 | 19.28 CNY |
| 8/28/2026 | 19.65 CNY |
| 8/27/2026 | 19.74 CNY |
| 8/26/2026 | 19.76 CNY |
| 8/25/2026 | 19.68 CNY |
| 8/24/2026 | 19.30 CNY |
| 8/21/2026 | 20.03 CNY |
| 8/20/2026 | 21.08 CNY |
| 8/19/2026 | 20.66 CNY |
| 8/18/2026 | 22.45 CNY |
| 8/17/2026 | 21.56 CNY |
| 8/14/2026 | 22.33 CNY |
| 8/13/2026 | 20.30 CNY |
| 8/12/2026 | 19.95 CNY |
| 8/11/2026 | 19.89 CNY |
Vcanbio Cell & Gene Engineering Corp Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Vcanbio Cell & Gene Engineering Corp Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB CNY |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB CNY |
| EBITM CNY |
| EBIT MARGIN% |
| NET INCOMEM CNY |
| NET INCOME GROWTH% |
| SHARESM |
| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.23 | 0.30 | 0.36 | 0.48 | 0.71 | 0.84 | 1.32 | 1.32 | 1.39 | 1.32 | 1.54 | 1.55 | 1.59 | 1.59 | 1.45 | 2.01 |
| -9.02 | 29.31 | 20.33 | 31.86 | 48.74 | 18.22 | 57.71 | – | 5.00 | -4.91 | 16.46 | 1.24 | 2.25 | -0.25 | -8.26 | 38.24 |
| 84.05 | 74.00 | 70.08 | 73.53 | 65.40 | 64.76 | 66.52 | 65.61 | 67.46 | 65.78 | 69.12 | 67.18 | 68.22 | 68.58 | 69.88 | 69.88 |
| 0.20 | 0.22 | 0.25 | 0.35 | 0.46 | 0.54 | 0.88 | 0.87 | 0.94 | 0.87 | 1.06 | 1.04 | 1.08 | 1.09 | 1.02 | 1.40 |
| 47.00 | 11.00 | 3.00 | 56.00 | 252.00 | 84.00 | 62.00 | 44.00 | 114.00 | -92.00 | 219.00 | 156.00 | 131.00 | 135.00 | 196.00 | 247.00 |
| 20.26 | 3.67 | 0.83 | 11.76 | 35.59 | 10.04 | 4.70 | 3.33 | 8.23 | -6.98 | 14.27 | 10.04 | 8.24 | 8.52 | 13.48 | 12.29 |
| 23.00 | 13.00 | 7.00 | 35.00 | 208.00 | 37.00 | 10.00 | 59.00 | 49.00 | -126.00 | 155.00 | 112.00 | 106.00 | 100.00 | 113.00 | – |
| 187.50 | -43.48 | -46.15 | 400.00 | 494.29 | -82.21 | -72.97 | 490.00 | -16.95 | -357.14 | -223.02 | -27.74 | -5.36 | -5.66 | 13.00 | – |
| 319.19 | 322.00 | 334.58 | 351.16 | 386.13 | 348.99 | 363.46 | 388.70 | 433.87 | 470.68 | 486.41 | 467.95 | 467.95 | 461.66 | 455.90 | 455.90 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Vcanbio Cell & Gene Engineering Corp generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Vcanbio Cell & Gene Engineering Corp retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Vcanbio Cell & Gene Engineering Corp's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Vcanbio Cell & Gene Engineering Corp has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Vcanbio Cell & Gene Engineering Corp's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Vcanbio Cell & Gene Engineering Corp stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Vcanbio Cell & Gene Engineering Corp Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Vcanbio Cell & Gene Engineering Corp business model & stock analysis
Vcanbio Cell & Gene Engineering Corp Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Vcanbio Cell & Gene Engineering Corp historical P/E ratio, EBIT multiple, and P/S ratio
Vcanbio Cell & Gene Engineering Corp annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down Vcanbio Cell & Gene Engineering Corp's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in Vcanbio Cell & Gene Engineering Corp's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare Vcanbio Cell & Gene Engineering Corp's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Vcanbio Cell & Gene Engineering Corp shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Vcanbio Cell & Gene Engineering Corp stock splits
Since 1993, a total of 9.223344 shares have been converted from one Vcanbio Cell & Gene Engineering Corp share.
Vcanbio Cell & Gene Engineering Corp Dividend History
3 years of dividend payments
Vcanbio Cell & Gene Engineering Corp Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 4/25/2024 | -CNY | -0.06CNY | 2.30 BCNY | - | 2024 Q1 |
| 4/25/2023 | -CNY | -0.00CNY | 1.93 BCNY | - | 2023 Q1 |
EESG©
Eulerpool ESG Scorecard© for the Vcanbio Cell & Gene Engineering Corp stock
EEnvironment
Environment
SSocial
Social
GGovernance (Corporate Governance)
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Vcanbio Cell & Gene Engineering Corp shareholder structure
| % | Name |
|---|---|
0.23027% | |
0.07386% | |
0.01583% | |
0.00320% | |
0.00068% | |
0.00050% |
Vcanbio Cell & Gene Engineering Corp Beneficial Ownership Filings (SEC 13D/G)
Vcanbio Cell & Gene Engineering Corp Executives and Management Board
14 members · avg. age 50 · 21 % women
Mr. Yu Zhang (39)
Deputy General Manager, Chief R&D Officer
2.42 M CNY
Management
Mr. Hongxiang Shi (41)
Deputy General Manager
Ms. Jiali Zhou (38)
Deputy General Manager
Board of Directors
Mr. Yong Wang (56)
Vice Chairman of the Board · since 2009
Mr. Xu Li (38)
Executive Deputy General Manager, Director · since 2015
Mr. Haibin Li (52)
Deputy General Manager, Director · since 2016
Mr. Xinzhe Yang (50)
Deputy General Manager, Secretary of the Board
Ms. Xiaoting Wang (41)
Finance Director
Mr. Hongqi Wang (60)
Vice Chairman of the Board, General Manager · since 2023
Frequently asked questions about Vcanbio Cell & Gene Engineering Corp
5 analysts currently rate the Vcanbio Cell & Gene Engineering Corp stock: 4 recommend buying, 1 holding and 0 selling.
Vcanbio Cell & Gene Engineering Corp Analyst Price Targets 2026
Converted at the current exchange rate, the Vcanbio Cell & Gene Engineering Corp share trades at 2.45 EUR (18.86 CNY).
The Vcanbio Cell & Gene Engineering Corp share (600645.SS) is listed on 1 stock exchanges, including: Shanghai (600645.SS).
No history available for Vcanbio Cell & Gene Engineering Corp.
The expected revenue of Vcanbio Cell & Gene Engineering Corp is 2.01 B CNY. This figure is based on current financial data and reflects the company's business performance.
The profit cannot currently be calculated for Vcanbio Cell & Gene Engineering Corp.
The P/E ratio cannot be calculated for Vcanbio Cell & Gene Engineering Corp at the moment.
The price-to-sales ratio (P/S) of Vcanbio Cell & Gene Engineering Corp is currently 4.28. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Vcanbio Cell & Gene Engineering Corp stock.
The Eulerpool Quality Score for Vcanbio Cell & Gene Engineering Corp is 3/10.
The ISIN of Vcanbio Cell & Gene Engineering Corp is CNE000000545. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Vcanbio Cell & Gene Engineering Corp is 600645.SS. The ticker symbol is used to trade Vcanbio Cell & Gene Engineering Corp shares on the stock exchange.
Vcanbio Cell & Gene Engineering Corp paid dividends every year for the past 0 years.
Vcanbio Cell & Gene Engineering Corp is assigned to the 'Health' sector.
To receive the latest dividend of Vcanbio Cell & Gene Engineering Corp from 8/16/2001 amounting to 0.01 CNY, you needed to have the stock in your portfolio before the ex-date on 8/10/2001.
The last dividend was paid out on 8/16/2001.
The dividends of Vcanbio Cell & Gene Engineering Corp are distributed in CNY.
Vcanbio Cell & Gene Engineering Corp stock
Vcanbio Cell & Gene Engineering Corp Peer Group
Vcanbio Cell & Gene Engineering Corp Ticker
Vcanbio Cell & Gene Engineering Corp FIGI
All fundamentals and in-depth analysis of Vcanbio Cell & Gene Engineering Corp
Our stock analysis for Vcanbio Cell & Gene Engineering Corp stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vcanbio Cell & Gene Engineering Corp. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.